Latest California Healthline Stories
Cities and Counties Unlikely To Heed FDA Warning On Importing Foreign Drugs
The Food and Drug Administration claims CanaRX, a company used by more than 500 cities, counties and school districts to help their employees get cheaper drugs from overseas, has sent “unapproved” and “misbranded” drugs to U.S. consumers, jeopardizing their safety.
Patients Question How FDA Approves Medical Devices
High-profile failures of implantable medical devices — such as certain hip joints and pelvic mesh — have prompted the Food and Drug Administration to revise its assessment process.
Podcast: KHN’s ‘What The Health?’ How Safe Are Your Supplements?
Alice Ollstein of Politico, Kimberly Leonard of the Washington Examiner and Anna Edney of Bloomberg News join KHN’s Julie Rovner to discuss the latest national health spending estimates, another FDA crackdown on dietary supplements and lawsuits between insurers and the federal government that could result in a windfall for consumers.
A ‘Fountain Of Youth’ Pill? Sure, If You’re A Mouse.
The race for the cure to aging sparks hope and hype among top scientists — plus billions of dollars in investment.
Trump Administration Salutes Parade Of Generic Drug Approvals, But Hundreds Aren’t For Sale
President Donald Trump and FDA officials have pointed to a surge in generic drug approvals, but a data analysis indicates almost half haven’t reached the market.
Why The U.S. Remains The World’s Most Expensive Market For ‘Biologic’ Drugs
Biologic drugs, made from living organisms, are big moneymakers partly because they have little competition from “biosimilars.” It’s a very different story in Europe.
Podcast: KHN’s ‘What The Health?’ New Year, New Health Proposals
Democratic governors and mayors are unveiling new ideas to control costs and expand coverage. The federal government shutdown has spared most health agencies, but not all. And learn the latest on that lawsuit out of Texas, which is threatening the Affordable Care Act once again. Margot Sanger-Katz of The New York Times, Anna Edney of Bloomberg News and Rebecca Adams of CQ Roll Call join KHN’s Julie Rovner to discuss these issues and, for “extra credit,” provide their favorite health policy stories of the week. Rovner also interviews KHN’s Jordan Rau about the latest “Bill of the Month.”
Health Care Industry Spends $30B A Year Pushing Its Wares, From Drugs To Stem Cell Treatment
Critics say patients are often misled by ads that advocate high-priced drugs or genetic tests.
When Medicine Makes Patients Sicker
The Food and Drug Administration is supposed to inspect all factories, foreign and domestic, that produce drugs for the U.S. market. But a KHN review of thousands of FDA documents — inspection records, recalls, warning letters and lawsuits — reveals how drugs that are poorly manufactured or contaminated can reach consumers.
Cómo afecta el cierre del gobierno a los programas de salud
Hay siete proyectos de ley pendientes, con presupuestos sin resolver, que impactan fuerte en iniciativas importantes relacionadas con la salud.